360° SearchNetwork Hot Spots Trends Time Series

DARA BioSciences Inc

Type: Company

Name: DARA BioSciences Inc

First reported Jun 18 2013 - Updated 9 hours ago - 3 reports

T3D Therapeutics wins exclusive global rights to DB959 from DARA BioSciences

T3D Therapeutics has obtained exclusive global rights to develop and commercialize oral, highly selective, dual nuclear receptor agonist DB959 from DARA BioSciences.Targeting peroxisome proliferator activated receptor delta (PPARd), DB959 was developed ... [Published Pharmaceutical Business Review - 9 hours ago]

Entities: DARA BioSciences Inc, Therapeutics, Receptor, Oncology

First reported Jun 18 2013 - Updated 23 hours ago - 2 reports

Dara licenses diabetes compound to new RTP firm with CNS focus

Dara BioSciences spent years developing DB959 for diabetes. Now it's been licensed to T3D Therapeutics, which plans to study it in Alzheimer's disease. Read why T3D is a good fit for DB959's new focus. ... [Published Local Tech Wire - 23 hours ago]

Entities: Diabetes, DARA BioSciences Inc, Therapeutics

First reported Jun 11 2013 - Updated Jun 11 2013 - 1 reports

Form 4 DARA BioSciences, Inc. For: May 10 Filed by: Richardson Paul John

StreetInsider.com - Form 4 DARA BioSciences, Inc. For: May 10 Filed by: Richardson Paul John ... [Published Street Insider - Jun 11 2013]

Entities: DARA BioSciences Inc, Paul John

First reported Jun 11 2013 - Updated Jun 11 2013 - 1 reports

Form 4 DARA BioSciences, Inc. For: May 10 Filed by: Heady Timothy James

StreetInsider.com - Form 4 DARA BioSciences, Inc. For: May 10 Filed by: Heady Timothy James ... [Published Street Insider - Jun 11 2013]

Entities: DARA BioSciences Inc

First reported Jun 03 2013 - Updated Jun 03 2013 - 1 reports

Dara Biosciences Enrolls Leading Oncology Centers in Breast Cancer Patient Registry

- CAPTURE: COMPLIANCE AND PREFERENCE FOR TAMOXIFEN REGISTRY Focuses on Gaining Insights into Aspects of Tamoxifen Therapy in Breast Cancer Patients- - Announced at American Society of Clinical Oncology (ASCO) Annual Meeting - RALEIGH, NC & CHICAGO, IL ... [Published Big News Network - Jun 03 2013]

Entities: DARA BioSciences Inc, Oncology, Breast Cancer, Tamoxifen, Patient

First reported Jun 03 2013 - Updated Jun 03 2013 - 2 reports

Tamoxifen

DARA Biosciences Enrolls Leading Oncology Centers in Breast Cancer Patient Registry

CAPTURE: Compliance and Preference for Tamoxifen Registry Focuses on Gaining Insights Into Aspects of Tamoxifen Therapy in Breast Cancer Patients Announced at American Society of Clinical Oncology (ASCO) Annual Meeting ... [Published Interest!ALERT - Jun 03 2013]

Entities: DARA BioSciences Inc, Breast Cancer, Oncology, Patient, Tamoxifen

First reported Jun 02 2013 - Updated Jun 02 2013 - 1 reports

DARA BioSciences, Inc. (DARA) - Financial and Strategic SWOT Analysis Review - new company profile report

- DARA BioSciences, Inc. (DARA BioSciences), formerly Point therapeutics, Inc. is a development stage pharmaceutical company engaged in the acquisition of therapeutic molecules and medical technologies from third parties, which the company advances its ... [Published TransWorldNews - Jun 02 2013]

Entities: DARA BioSciences Inc, SWOT Analysis, Corporate Strategy, Molecule, Threat

First reported May 31 2013 - Updated May 31 2013 - 1 reports

Form 4 DARA BioSciences, Inc. For: May 30 Filed by: COCHRANE HAYWOOD D

StreetInsider.com - Form 4 DARA BioSciences, Inc. For: May 30 Filed by: COCHRANE HAYWOOD D ... [Published Street Insider - May 31 2013]

Entities: DARA BioSciences Inc

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Form 4 DARA BioSciences, Inc. For: May 23 Filed by: Heady Timothy James

StreetInsider.com - Form 4 DARA BioSciences, Inc. For: May 23 Filed by: Heady Timothy James ... [Published Street Insider - May 24 2013]

Entities: DARA BioSciences Inc

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Top Pharmaceutical Leaders Gathering in East Brunswick, NJ on Sept 17-18 for Groundbreaking Event

- NEW YORK -- To succeed in the pharmaceutical industry, insiders grasp that what you know and who you know are equally important. The best place to get the right answers and to stay ahead of the curve is at the Pharma CI Conference & Exhibition on September ... [Published Prlog - May 22 2013]

Entities: East Brunswick (United States), Pfizer Inc, Upsher-Smith Laboratories, Inc., DARA BioSciences Inc

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Can Dara Biosciences bust out of this slump?

DARA Biosciences (Nasdaq: DARA) execs say the Raleigh company is about to bust out of its slump — and that all it needs is time. Nasdaq, however, is only giving the pharma six months.The pharma, which recently switched its focus to in-licensing oncology ... [Published Triangle Business Journal - May 21 2013]

Entities: DARA BioSciences Inc, Raleigh (North Carolina, United States), Oncology

First reported Apr 11 2013 - Updated Apr 11 2013 - 1 reports

Dara Biosciences: Don't Believe The Hype Surrounding This Biopharma

By EnhydrisPECorp : Yesterday, an article appeared in Seeking Alpha by PropThink writer, Jason Napodano, CFA, in which he claims Dara Biosciences ( DARA ) will more than double in PPS. Specifically, DARA is currently trading at .88 cents a share, ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 11 2013]

Entities: DARA BioSciences Inc, Jason Napodano, KRN5500

Quotes

..." T3D Therapeutics founder and chief executive officer John Didsbury said, "Given the neuroprotectant potential of DB959's mechanism of action and the growing evidence of metabolic disorders contributing to CNS diseases, we are excited to commence an aggressive development program for DB959." Latest News

T3D Therapeutics wins exclusive global rights to DB959 from DARA BioSciences [Published Pharmaceutical Business Review - 9 hours ago]

T3D Therapeutics' founder and CEO, John Didsbury, PhD, said: "With today's highly competitive diabetes and dyslipidemia market, we believe that DB959 will be better positioned to address unmet medical needs for new central nervous system (CNS) therapies. Given the neuroprotectant potential of DB959's mechanism of action and the growing evidence of metabolic disorders contributing to CNS diseases, we are excited to commence an aggressive development programme for DB959"

DARA BioSciences Inc grants T3D Therapeutics its exclusive worldwide rights to DB959 for treating ... [Published Individual.com - 14 hours ago]

David J Drutz, MD, DARA's Chief Executive Officer and Chief Medical Officer, stated, "We are very pleased to have reached an agreement with T3D Therapeutics to enable the further development of DB959.$ This program no longer fits into the strategic focus of DARA as we have shifted our corporate attention to the commercialization of oncology supportive care products.$ The T3D Therapeutics team, including John Didsbury, who was Chief Scientific Officer of DARA from 2005 to 2009, is comprised of leading experts in the field of PPAR science and are extremely familiar with the compound.$ We believe they will apply the necessary resources to explore DB959 in multiple, potential high-value indications.$ Importantly, the agreement affords DARA upfront considerations as well as future potential revenue based on progression of the DB959 developmental program."

DARA BioSciences Grants T3D Therapeutics Exclusive Worldwide Rights to Develop and Commercialize ... [Published Stockwatch - Jun 18 2013]

...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."

DARA, AAU, GPRE, BVSN, SMSI, ENMD Are Seasonally Ripe To Go Down In the Next Five Weeks [Published Individual.com - Jun 04 2013]

More Content

sort by: Date \| Relevance
T3D Therapeutics wins exclusive global rights t... [Published Pharmaceutical Business Review - 9 hours ago]
DARA BioSciences Inc grants T3D Therapeutics it... [Published Individual.com - 14 hours ago]
Dara licenses diabetes compound to new RTP firm... [Published Local Tech Wire - 23 hours ago]
T3D Licenses Drug Candidate from Dara, Repositi... [Published Genetic Engineering News - Jun 18 2013]
Dara BioSciences grants T3D Therapeutics worldw... [Published Yahoo! Finance - Jun 18 2013]
Form 8-K DARA BioSciences, Inc. For: Jun 17 [Published Street Insider - Jun 18 2013]
DARA BioSciences Grants T3D Therapeutics Exclus... [Published Stockwatch - Jun 18 2013]
DARA BioSciences Grants T3D Therapeutics Exclus... [Published Marketwire - Breaking News Releases - Jun 18 2013]
Form 4 DARA BioSciences, Inc. For: May 10 Filed... [Published Street Insider - Jun 11 2013]
Form 4 DARA BioSciences, Inc. For: May 10 Filed... [Published Street Insider - Jun 11 2013]
DARA, AAU, GPRE, BVSN, SMSI, ENMD Are Seasonall... [Published Individual.com - Jun 04 2013]
Dara Biosciences Enrolls Leading Oncology Cente... [Published Big News Network - Jun 03 2013]
DARA Biosciences Enrolls Leading Oncology Cente... [Published Interest!ALERT - Jun 03 2013]
DARA Biosciences Enrolls Leading Oncology Cente... [Published Street Insider - Jun 03 2013]
DARA Biosciences Enrolls Leading Oncology Cente... [Published Marketwire - Breaking News Releases - Jun 03 2013]
DARA BioSciences, Inc. (DARA) - Financial and S... [Published TransWorldNews - Jun 02 2013]
Form 4 DARA BioSciences, Inc. For: May 30 Filed... [Published Street Insider - May 31 2013]
DARA BioSciences, Inc. (DARA) - Pharmaceuticals... [Published Live-PR.com - May 24 2013]
Form 4 DARA BioSciences, Inc. For: May 23 Filed... [Published Street Insider - May 24 2013]
Top Pharmaceutical Leaders Gathering in East Br... [Published Prlog - May 22 2013]
Can Dara Biosciences bust out of this slump? [Published Triangle Business Journal - May 21 2013]
Helsinn y DARA anuncian el lanzamiento en EE. U... [Published PR Newswire: Policy & Public Interest - Apr 23 2013]
Dara Biosciences: Don't Believe The Hype Surrou... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 11 2013]
4 Healthcare Stock Stories For Midweek Perusal [Published Wall St. Cheat Sheet - Apr 03 2013]
DARA BioSciences Enters Into Distribution Agree... [Published Marketwire - Breaking News Releases - Apr 03 2013]
8-K - DARA BioSciences, Inc. (0000919745) (Filer) [Published SEC Filings - Apr 01 2013]
Biotech Industry Looks to Benefit From FDA's Ne... [Published Marketwire - Breaking News Releases - Mar 20 2013]
DARA BioSciences to Present at 25th Annual ROTH... [Published Marketwire - Breaking News Releases - Mar 18 2013]
New Programs Designed to Speed Up Approval Proc... [Published Marketwire - Breaking News Releases - Mar 13 2013]
8-K - DARA BioSciences, Inc. (0000919745) (Filer) [Published SEC Filings - Mar 05 2013]

Blogs

sort by: Date \| Relevance
4 Healthcare Stock Stories For Midweek Perusal [Published Wall St. Cheat Sheet - Apr 03 2013] Astex Pharmaceuticals ( NASDAQ:ASTX ): Current price $5.49 On Wednesday, Astex announced the acceptance of thirteen abstracts that cover internal and partner funded pipeline product data, for presentation at the American Association for Cancer Research ...
Quest Diagnostics Unafraid of the SCOTUS, Stryk... [Published Wall St. Cheat Sheet - Dec 31 2012] The idea that the United States Supreme Court could strike down patents on human genes might be quite worrisome to firms such as Quest Diagnostics Incorporated ( NYSE:DGX ), which bought a company for the rights to such patents for $740 million in ...

Press Releases

sort by: Date \| Relevance
DARA BioSciences Grants T3D Therapeutics Exclus... [Published Marketwire - Breaking News Releases - Jun 18 2013]
DARA Biosciences Enrolls Leading Oncology Cente... [Published Marketwire - Breaking News Releases - Jun 03 2013]
Helsinn y DARA anuncian el lanzamiento en EE. U... [Published PR Newswire: Policy & Public Interest - Apr 23 2013]
DARA BioSciences Enters Into Distribution Agree... [Published Marketwire - Breaking News Releases - Apr 03 2013]
Biotech Industry Looks to Benefit From FDA's Ne... [Published Marketwire - Breaking News Releases - Mar 20 2013]